CNO Beats on 47% Operating EPS Growth, Raises 2026 Guidance 9% at Midpoint
CNO sits 43% above its 52-week low of $38.99.
Summary
CNO reported 3Q26 net operating income of $179.1 million ($1.90 per diluted share), up 47%, and raised full-year 2026 operating EPS guidance to $5.05-$5.15, a 9% midpoint increase. The quarter included a $44.9 million favorable actuarial review benefit and $60 million of share repurchases.
Key Events · Earnings and Guidance · CNO
-
3Q26 Operating EPS Up 47%
Net operating income was $179.1 million, or $1.90 per diluted share, versus $127.2 million, or $1.29, in 3Q25. Net income was $161.1 million, or $1.71 per diluted share.
-
Guidance Raised 9% at Midpoint
Full-year 2026 operating EPS guidance is now $5.05-$5.15, up 9% at the midpoint from prior guidance, with an 18.6%-18.8% expense ratio and $220-$240 million of free cash flow.
-
Actuarial Review Adds $44.9M
The comprehensive annual actuarial review had a $44.9 million net favorable impact ($0.48 per diluted share); excluding significant items, operating EPS was $1.42, up 48%.
-
Third Bermuda Reinsurance Closed
On October 1, 2026, CNO closed its third reinsurance transaction with its wholly owned Bermuda affiliate, reinsuring approximately $270 million of inforce graded benefit life statutory reserves from Colonial Penn.
Analysis · CNO · Finance
The headline beat rests on net operating income of $179.1 million ($1.90 per diluted share), up 47% from $127.2 million ($1.29) in 3Q25. Roughly a quarter of that came from a one-time boost: the annual actuarial review added $44.9 million ($0.48 per share), so operating EPS excluding significant items was $1.42, still up 48%. Management raised full-year 2026 operating EPS guidance to $5.05-$5.15, a 9% increase at the midpoint, which tells investors the underlying sales and margin trend is holding rather than the quarter being a one-off. Sales grew for a 17th consecutive quarter and producing agent counts rose for a 15th straight quarter, supporting the fee and margin base. The company also closed its third Bermuda reinsurance transaction on October 1, ceding about $270 million of Colonial Penn graded benefit life statutory reserves, which frees capital. Capital return continued with $60 million of buybacks in the quarter at an average $54.52 per share, leaving $240.4 million of repurchase authority. The main caveats are the heavy reliance on the actuarial review for the headline beat and a $22.1 million deferred tax valuation allowance tied to capital loss carryforwards, which hit GAAP net income but not operating results.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 38.8% of the 970 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNO was trading at $55.75 on NYSE in the Finance sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $38.99 to $57.59. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.